Prof Mohamed Hassany, MD
Hepatology — Dermatology Clinic of National Hepatology and Tropical Medicine Research Institute, Egypt
Mohamed Hassany
LeadR Profile
Hepatology
Subspecialties: Gastroenterology - Public Health - Infectiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2012 - 2026
Number : 151
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Implementation of a national rheumatic fever and rheumatic heart disease prevention and control program in Egypt: rationale and objectives. registries, heart diseases, heart, rheumatic fever, schools, rheumatic heart disease, research | Front Cardiovasc Med | 2026 | 0 |
| AASLD's opportunity to lead national monitoring of the World Health Assembly resolution on steatotic liver disease. liver diseases, liver | Hepatology | 2026 | 0 |
| From viral clearance to cancer prevention: the next phase of hepatitis elimination. liver diseases, neoplasms, gastrointestinal diseases, hepatitis | Lancet Gastroenterol Hepatol Top journal | 2026 | 0 |
| A WHA resolution on Steatotic liver diseases -A Global Call to Action. liver diseases, liver | J Hepatol Top journal | 2026 | 0 |
| Primary health care-oriented reforms: the political economy dynamics underlying health-system shifts across nine countries. developing countries, physicians, health planning, private sector | Health Policy Plan | 2026 | 0 |
Clinical Studies 13
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Efficacy and Safety of Dapagliflozin in Patients With Non alcoholic Steatohepatitis NCT05254626 — liver diseases, diabetes mellitus, sodium-glucose transporter 2 inhibitors, safety, blood, serum, fibrosis, non-alcoholic fatty liver disease, biopsy, liver, alcoholics, drug-related side effects and adverse reactions, pioglitazone, therapeutics, fatty liver, fatty liver, alcoholic, diabetes mellitus, type 2 | Phase 2 | Active not recruiting | 2022 |
LeadR Networks
Main global connection map